| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Acquisition of imago biosciences, inc., net of cash acquired | - | - | - | 0 |
| Other | -114 | 15 | 20 | 70 |
| Net cash used in investing activities | -2,540 | -2,257 | -1,487 | -6,290 |
| Net change in short-term borrowings | 63 | 48 | - | - |
| Proceeds from issuance of debt | 5,962 | 0 | - | 3,599 |
| Payments on debt | 2,501 | 2,500 | 2,500 | 751 |
| Dividends paid to stockholders | 6,158 | 4,127 | 2,050 | 5,889 |
| Purchases of treasury stock | 3,832 | 2,509 | 1,164 | 817 |
| Proceeds from exercise of stock options | 45 | 31 | 19 | 165 |
| Other | -252 | -254 | -60 | -330 |
| Net cash used in financing activities | -6,673 | -9,311 | -5,755 | -4,023 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 540 | 530 | 156 | 74 |
| Net increase in cash, cash equivalents and restricted cash | 4,942 | -5,245 | -4,586 | 7,779 |
| Cash and cash equivalents at beginning of period | 13,318 | 13,318 | 13,318 | 6,909 |
| Cash and cash equivalents at end of period | 18,260 | 8,073 | 8,732 | 14,688 |
Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK)